Stocks / MRNA
MRNA stock forecast
MODERNA INC · Healthcare · Biotechnology
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
MRNA is not among the 20 largest holdings published for 2026 Q4. See the portfolio
MRNA against the S&P 500
| Period | MRNA | S&P 500 (SPY) |
|---|---|---|
| 1 month | -13.3% | -4.7% |
| 3 months | +12.9% | -4.8% |
| Year to date | +567.3% | +7.9% |
| 1 year | +689.7% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $196.79 |
| Market cap | 79.63 Billion |
| P/E (trailing 12 months) | -27.8 |
| P/S (trailing 12 months) | 31.5 |
| P/B (latest quarter) | 15.0 |
| Gross margin | 28.0% |
| Net profit margin | -110.5% |
| Return on equity | -37.6% |
| Beta | 2.4 |
As of November 6, 2026.
MRNA and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC | 97.81 Billion | Outperform | REGN vs MRNA |
| INCY | INCYTE CORP | 24.01 Billion | Greatly Outperform | MRNA vs INCY |
| VRTX | VERTEX PHARMACEUTICALS INC | 136.01 Billion | Outperform | VRTX vs MRNA |
| TECH | BIO-TECHNE CORP | 11.43 Billion | Underperform | MRNA vs TECH |
Questions
What does the Upfront Investment model say about MRNA?
The model rates MODERNA INC (MRNA) "Greatly Underperform" as of November 18, 2026, which means its medium-term return forecast is in the bottom fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the MRNA rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is MRNA in the Upfront Investment model portfolio?
MRNA is not among the 20 largest holdings published for 2026 Q4.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.